Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Advanced Proteome Therapeutics in the next few years
Pros
?
S********** s********
?
B****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Advanced Proteome Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Advanced Proteome Therapeutics | - | - | - | - | - | - | - |
| Satellos Bioscience Inc. | -9.590% | 2.062% | 17.160% | 22.222% | -29.286% | 58.084% | - |
| Vaxart Inc. | -21.240% | 4.494% | 1.384% | -66.186% | -56.528% | -89.345% | -94.624% |
| Larimar Therapeutics Inc. | -4.570% | 0.602% | -11.170% | -47.402% | -10.215% | 0.000% | -76.934% |
News
Palantir’s Defense Partnerships Fuel Its Growth Story
Investors have many reasons to believe in Palantir Technologies Inc. (NASDAQ: PLTR) as a long-term growth stock. One of the original chapters of the company’s bull thesis is its proximity and
enGene Posts 78% Expense Jump in Q3
enGene (NASDAQ:ENGN), a clinical-stage gene therapy company advancing treatments for bladder cancer, released its fiscal 2025 third-quarter earnings on Sept. 11, 2025. The period was highlighted by
Richmond Terrace Capital Secures €900 Million from European Pension Leaders
CITY OF LONDON, GB / ACCESS Newswire / September 11, 2025 / Richmond Terrace Capital, a leading London-based investment management company, is pleased to announce that a consortium of leading
